Menlo Therapeutics Inc

4085 Campbell Avenue
Suite 200
Menlo Park
California
CA 94025
United States

Tel: 650-486-1416

Email: info@menlotx.com

Show jobs for this employer

About Menlo Therapeutics Inc

Menlo Therapeutics Inc. (formerly Tigercat Pharma, Inc.) is a clinical stage pharmaceutical company focused on the development and commercialization of serlopitant for the treatment of severe, chronic pruritus (itch). Serlopitant (VPD-737) is a potent oral NK1 receptor antagonist that Menlo Therapeutics exclusively licensed from Merck in 2012. Menlo Therapeutics investors include Vivo Capital, F-Prime Capital, Presidio Partners and Remeditex Ventures.
YEAR FOUNDED:
2011
LEADERSHIP:
CEO: Steven Basta
CMO: Paul Kwon

22 articles with Menlo Therapeutics Inc